Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Theralink Technologies, Inc. (THER)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
15000 West 6th Avenue 80401
Golden, CO, US
Golden, CO, US
CEO
Michael I. Ruxin
Website
theralink.com
IPO
2010-04-01
CIK 1362703 ISIN US88339Q1094
Also trades on
Other OTC · OBMP (USD)
Other OTC · THER (USD)
Description
Theralink Technologies, Inc., headquartered in Golden, Colorado, is a commercial-stage enterprise specializing in precision medicine and the generation of crucial molecular data. The company is dedicated to advancing and bringing to market innovative cancer immunotherapy products. Utilizing its proprietary platform, which focuses on phosphoprotein and protein biomarkers, alongside its sophisticated laboratory-developed test (LDT) technology, Theralink addresses diverse aspects of oncology and pharmaceutical research. Through their specialized Theralink Reverse Phase Protein Array assays, they provide highly accurate oncology data. This information enables the biopharmaceutical industry and clinical oncologists to more precisely predict which patients will respond to, or be resistant to, both FDA-approved and investigational drug treatments. Ultimately, Theralink's diagnostic assays deliver vital, actionable insights that benefit physicians, patients, and biopharmaceutical companies operating within the field of cancer care. The company adopted its current name, Theralink Technologies, Inc., in September 2020, having previously operated as OncBioMune Pharmaceuticals, Inc.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
56.8K
Beta
8.99
Float Shares
6.15B
Free Float %
100.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +9,900.00% | +0.00% | -94.44% | -99.99% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Quality scores
Altman Z-Score
-71.35
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+6.9% ★ Q3'23: -41.3% (vs Q3'22)
-
EPS growth Biotechnology: +29.7%-127.3% Q3'23: +223.1% (vs Q3'22)
-
FCF margin FCF growth · Biotechnology: +16.2%-6,497.2% Q3'23: -925.7% (vs Q3'22)
-
EBIT margin Biotechnology: +0.0%-1,479.8% Q3'23: +0.0% (vs Q3'22)
-
ROIC Biotechnology: -16.1%— Q3'23: +0.0% (vs Q3'22)
-
Share dilution Biotechnology: -3.4%+4.6% Q3'23: +4.6% (vs Q3'22)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-2.26× Q3'23: -1.99× (vs Q3'22)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-4.35M
OE per share TTM
0.00
Owner's Yield
-70,791.04%
Maintenance CapEx ratio
5.56%
Maint CapEx / Avg PPE
301.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
9
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | American Capital Ventures, Inc. | 150.67M | 36.80% | 150.67M | — | — | 10.00 | OO | or Place of Organization | 2015-05-27 | ↗ |
| 2 | Leone Group, LLC | 150.67M | 36.80% | 150.67M | — | — | 10.00 | OO | or Place of Organization | 2015-05-27 | ↗ |
| 3 | Manuel Cosme Odabachian | 30.58M | 25.00% | 30.58M | — | 30.58M | 10.00 | IN | Citizenship or Place of Organization | 2017-03-20 | ↗ |
| 4 | Carlos Fernando Alamán Volnie | 30.58M | 25.00% | 30.58M | — | 30.58M | 10.00 | IN | Citizenship or Place of Organization | 2017-03-20 | ↗ |
| 5 | ROBERT L. ELLIOTT, JR. | 16.93M | 31.10% | 16.93M | — | 16.93M | — | IN | UNITED STATES | 2016-02-04 | ↗ |
| 6 | F. HEAD, PH. D. | 16.93M | 31.10% | 16.93M | — | 16.93M | — | IN | STATES | 2016-02-04 | ↗ |
| 7 | KUCHARCHUK | 5.00M | 9.20% | 5.00M | — | 5.00M | — | IN | STATES | 2016-02-04 | ↗ |
| 8 | Cameron Durrant | 4.25M | 20.70% | 4.25M | — | 4.25M | 10.00 | IN | Dr. Durrant is a dual citizen of Australia and the United Kingdom | 2010-05-28 | ↗ |
| 9 | Diagnostics, Inc. | 1.0K | 99.00% | 1.0K | — | 1.0K | — | CO | Nevada | 2020-06-15 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
5
Sells
0
Shares acquired
1.05B
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+1,045,702,451
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-04-22 | Busch Jeffrey | Director | A-Award | A | Common Stock Purchase Warrant | 44,314,286 | 0.00 | 132.9K | 44,314,286 | — | ↗ |
| 2022-12-05 | Zaslavsky Faith | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-11-29 | Schwartz Matthew Wilson | Director | J-Other | A | 10% O.I.D. Senior Secured Convertible Debenture | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-11-29 | Holley Danica | Director | J-Other | D | 8% Convertible Promissory Note | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-11-29 | Busch Jeffrey | Director | J-Other | A | Common Stock Purchase Warrant | 88,424,286 | 0.00 | 265.3K | 88,424,286 | — | ↗ |
| 2022-09-16 | Schwartz Matthew Wilson | Director | A-Award | A | Stock Option (right to buy) | 5,191,080 | 0.00 | 18.7K | 5,191,080 | — | ↗ |
| 2022-09-16 | RUXIN MICHAEL I | Director / Officer | A-Award | A | Stock Option (right to buy) | 469,738,712 | 0.00 | 1.69M | 469,738,712 | — | ↗ |
| 2022-09-16 | FORS YVONNE | Director | A-Award | A | Stock Option (right to buy) | 6,488,851 | 0.00 | 23.4K | 6,488,851 | — | ↗ |
| 2022-09-16 | Chilcott, III Thomas E. | Officer | A-Award | A | Stock Option (right to buy) | 94,545,096 | 0.00 | 340.4K | 94,545,096 | — | ↗ |
| 2022-09-16 | Busch Jeffrey | Director / Officer | A-Award | A | Stock Option (right to buy) | 469,738,712 | 0.00 | 1.69M | 469,738,712 | — | ↗ |
| 2022-06-15 | Holley Danica | Director | J-Other | A | Warrants (right to buy) | 2,100,840 | 0.00 | 10.1K | 2,100,840 | — | ↗ |
| 2022-04-05 | Schwartz Matthew Wilson | Director | J-Other | A | 8% Convertible Promissory Note | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-04 | Holley Danica | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-01 | Schwartz Matthew Wilson | Director | — | D | Common Stock | 0 | 0.00 | — | 61,380,192 | — | ↗ |
| 2020-09-24 | Chilcott, III Thomas E. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-18 | FORS YVONNE | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-18 | Busch Jeffrey | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-05 | RUXIN MICHAEL I | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-05 | KUCHARCHUK ANDREW ALBERT | Director | A-Award | A | Series D-2 Convertible Preferred Stock | 241 | 0.00 | 0.02 | 241 | — | ↗ |
| 2020-06-05 | Avant Diagnostics, Inc | 10% Owner | — | D | Series D-1 Convertible Preferred Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-05-07 | KUCHARCHUK ANDREW ALBERT | Officer | A-Award | A | Shares of Common Stock | 283,334 | 0.06 | 17.0K | 290,001 | — | ↗ |
| 2020-05-07 | HEAD JONATHAN FREDERICK | Director | A-Award | A | Shares of Common Stock | 166,667 | 0.06 | 10.0K | 189,236 | — | ↗ |
| 2019-12-26 | Barnett Brian Gill | Officer | — | D | Stock Option (right to buy) | 8,347,245 | 0.01 | 100.2K | 0 | — | ↗ |
| 2019-05-08 | Barnett Brian Gill | Officer | — | D | Employee Stock Option (right to buy) | 1,000,000 | 0.01 | 13.5K | 0 | — | ↗ |
| 2019-04-24 | RICE CHARLES L JR | Director | A-Award | A | Employee Stock Option (right to buy) | 3,000,000 | 0.01 | 30.0K | 3,000,000 | — | ↗ |
| 2019-04-24 | Hoverman Daniel S. | Director | A-Award | A | Employee Stock Option (right to buy) | 3,000,000 | 0.01 | 30.0K | 3,000,000 | — | ↗ |
| 2019-04-24 | HOLCOMB ROBERT NEAL | Director | A-Award | A | Employee Stock Option (right to buy) | 3,000,000 | 0.01 | 30.0K | 3,000,000 | — | ↗ |
| 2019-04-24 | Barnett Brian Gill | Director | A-Award | A | Employee Stock Option (right to buy) | 8,347,245 | 0.01 | 100.2K | 8,347,245 | — | ↗ |
| 2018-05-09 | RICE CHARLES L JR | Director | A-Award | A | Option (right to buy) | 3,000,000 | 0.01 | 40.5K | 3,350,000 | — | ↗ |
| 2018-05-09 | KUCHARCHUK ANDREW ALBERT | Officer | A-Award | A | Option (right to buy) | 3,000,000 | 0.01 | 40.5K | 5,000,000 | — | ↗ |
| 2018-05-09 | Hoverman Daniel S. | Director | A-Award | A | Stock Option (right to buy) | 3,000,000 | 0.01 | 40.5K | 3,000,000 | — | ↗ |
| 2018-05-09 | HOLCOMB ROBERT NEAL | Director | — | D | Option (right to buy) | 3,000,000 | 0.01 | 40.5K | 0 | — | ↗ |
| 2018-05-09 | HEAD JONATHAN FREDERICK | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 3,000,000 | 0.01 | 40.5K | 3,000,000 | — | ↗ |
| 2018-03-19 | HOLCOMB ROBERT NEAL | Director | — | D | Common Stock | 0 | 0.00 | — | 1,266,668 | — | ↗ |
| 2017-04-17 | RICE CHARLES L JR | Director | A-Award | A | Employee Stock Option (right to buy) | 350,000 | 0.27 | 94.5K | 350,000 | — | ↗ |
| 2017-04-17 | Hoverman Daniel S. | Director | A-Award | A | Stock Option (right to buy) | 350,000 | 0.27 | 94.5K | 350,000 | — | ↗ |
| 2017-03-10 | Volnie Carlos Fernando Alaman | Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 30,579,006 | — | ↗ |
| 2017-03-10 | Odabachian Manuel Cosme | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 30,579,007 | — | ↗ |
| 2017-03-10 | KUCHARCHUK ANDREW ALBERT | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 2,000,000 | 0.25 | 500.0K | 2,000,000 | — | ↗ |
| 2017-03-10 | HEAD JONATHAN FREDERICK | Director / Officer / 10% Owner | J-Other | A | Series B Preferred Stock | 2,892,000 | 0.00 | — | 2,892,000 | — | ↗ |
| 2016-02-18 | Hoverman Daniel S. | Director | A-Award | A | Common Stock | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2015-12-30 | Hoverman Daniel S. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-11-18 | RICE CHARLES L JR | Director | A-Award | A | Common Stock | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2015-09-02 | KUCHARCHUK ANDREW ALBERT | Director / Officer | A-Award | A | Common stock | 5,000,000 | 0.00 | — | 5,000,000 | — | ↗ |
| 2015-09-02 | HEAD JONATHAN FREDERICK | Director / Officer | S-Sale | D | Common stock | 1,025,000 | 0.00 | 1.0K | 16,926,078 | — | ↗ |
| 2015-09-02 | ELLIOT ROBERT LANGE JR | Director / 10% Owner | A-Award | A | Common stock | 17,951,079 | 0.00 | — | 17,951,079 | — | ↗ |
| 2015-08-27 | Leone Group, LLC | 10% Owner | J-Other | A | Common Stock | 666,666 | 0.00 | 2.0K | 1,648,831 | — | ↗ |
| 2015-08-27 | American Capital Ventures, Inc. | 10% Owner | J-Other | A | Common Stock | 666,666 | 0.00 | 2.0K | 1,648,831 | — | ↗ |
| 2015-06-17 | Leone Group, LLC | 10% Owner | J-Other | A | Common Stock | 3,188,546 | 0.00 | 9.6K | 136,082,500 | — | ↗ |
| 2015-06-17 | American Capital Ventures, Inc. | 10% Owner | J-Other | A | Common Stock | 3,188,546 | 0.00 | 9.6K | 136,082,500 | — | ↗ |
| 2015-05-18 | Leone Group, LLC | 10% Owner | S-Sale | D | Common Stock | 17,774,136 | 0.00 | 1.8K | 132,893,954 | — | ↗ |
| 2015-05-18 | DIETRICH Constantin | Director / Officer | P-Purchase | A | Common Stock | 17,774,136 | 0.00 | 1.8K | 35,848,272 | — | ↗ |
| 2015-05-18 | American Capital Ventures, Inc. | 10% Owner | S-Sale | D | Common Stock | 17,774,136 | 0.00 | 1.8K | 132,893,954 | — | ↗ |
| 2015-04-20 | DIETRICH Constantin | Director / Officer | J-Other | D | Common Stock | 17,774,136 | 0.00 | — | 18,074,136 | — | ↗ |
| 2015-04-14 | DIETRICH Constantin | Director / Officer | P-Purchase | A | Common Stock | 17,774,136 | 0.00 | 9.95 | 35,848,272 | — | ↗ |
| 2015-03-10 | Leone Group, LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 150,668,090 | — | ↗ |
| 2015-03-10 | DIETRICH Constantin | Director / Officer | S-Sale | D | Common Stock | 300,000 | 0.00 | 30.00 | 0 | — | ↗ |
| 2015-03-10 | CARUSONE JOSEPH | Director / Officer | S-Sale | D | Common Stock | 2,100,000 | 0.00 | 210.00 | 0 | — | ↗ |
| 2015-03-10 | American Capital Ventures, Inc. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 150,668,090 | — | ↗ |
| 2013-04-05 | Durrant Cameron | Director / Officer / 10% Owner | P-Purchase | D | common stock | 4,250,000 | 0.01 | 51.0K | 0 | — | ↗ |
| 2013-04-05 | DIETRICH Constantin | Director / 10% Owner | P-Purchase | A | common stock | 4,250,000 | 0.01 | 51.0K | 4,250,000 | — | ↗ |
| 2013-04-05 | CARUSONE JOSEPH | Director / Officer | P-Purchase | A | common stock | 400,000 | 0.02 | 9.6K | 1,400,000 | — | ↗ |
| 2013-02-15 | DIETRICH Constantin | Director | — | I | common stock | 0 | 0.00 | — | 100,000 | — | ↗ |
| 2013-02-15 | ARCURI Joseph | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2011-12-15 | Richardson Paul John | Director | — | D | stock options | 50,000 | 1.00 | 50.0K | 0 | — | ↗ |
| 2011-03-04 | Tousley David L. | Director / Officer | A-Award | A | stock options | 690,000 | 1.14 | 786.6K | 690,000 | — | ↗ |
| 2011-03-04 | Rodriguez Jorge Enrique | Officer | A-Award | A | stock options | 420,000 | 1.14 | 478.8K | 420,000 | — | ↗ |
| 2011-02-09 | Tousley David L. | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2011-02-09 | Durrant Cameron | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2010-11-17 | Tousley David L. | Director / Officer | — | D | common stock | 0 | 0.00 | — | 400,000 | — | ↗ |
| 2010-11-17 | Rodriguez Jorge Enrique | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2010-11-03 | CARUSONE JOSEPH | Director / Officer | J-Other | D | common stock | 3,700,000 | 0.00 | — | 600,000 | — | ↗ |
| 2010-07-02 | CARUSONE JOSEPH | Director / Officer / 10% Owner | S-Sale | D | common stock | 1,050,000 | 0.01 | 12.6K | 4,300,000 | — | ↗ |
| 2010-05-20 | Durrant Cameron | 10% Owner | — | D | common stock | 0 | 0.00 | — | 4,250,000 | — | ↗ |
| 2010-05-20 | CARUSONE JOSEPH | Director / Officer / 10% Owner | S-Sale | D | common stock | 4,650,000 | 0.01 | 55.8K | 5,350,000 | — | ↗ |
| 2008-11-05 | CARUSONE JOSEPH | Director / Officer | P-Purchase | A | common stock | 400,000 | 0.10 | 40.0K | 400,000 | — | ↗ |
| 2008-08-18 | OPEX ENERGY CORP. | 10% Owner | — | D | common stock | 0 | 0.00 | — | 5,000,000 | — | ↗ |
| 2008-08-18 | CARUSONE JOSEPH | Director / Officer | — | I | common stock | 0 | 0.00 | — | 5,000,000 | — | ↗ |
| 2007-06-21 | Cole Brian | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 200,000 | — | ↗ |
| 2007-02-07 | Gregovic Konstantin | Director | — | D | Common Stock | 0 | 0.00 | — | 1,000 | — | ↗ |
| 2006-11-15 | Perger Shawn | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 5,000,000 | — | ↗ |
| 2006-08-29 | Stephenson Laurence | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 2,000 | — | ↗ |
| 2004-04-05 | LORTZ W MARK | Director / Officer | D-Return | D | Employee Stock Option (right to buy) | 100,269 | 20.20 | 2.03M | 0 | — | ↗ |
| 2004-04-05 | LORD JONATHAN T MD | Director | D-Return | D | Stock Option (right to buy) | 30,000 | 9.05 | 271.5K | 0 | — | ↗ |
| 2004-04-05 | JAFFE ROSS A MD | Director | D-Return | D | Stock Option (right to buy) | 5,000 | 21.25 | 106.3K | 0 | — | ↗ |
| 2004-01-05 | LORTZ W MARK | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 100,269 | 20.20 | 2.03M | 100,269 | — | ↗ |
| 2003-12-26 | LORTZ W MARK | Director / Officer | S-Sale | D | Common Stock | 3,333 | 18.37 | 61.2K | 547,490 | — | ↗ |
| 2003-12-23 | LORTZ W MARK | Director / Officer | G-Gift | D | Common Stock | 5,000 | 0.00 | — | 550,823 | — | ↗ |
| 2003-12-18 | LORTZ W MARK | Director / Officer | S-Sale | D | Common Stock | 1,667 | 17.90 | 29.8K | 555,823 | — | ↗ |
| 2003-11-17 | LORTZ W MARK | Director / Officer | S-Sale | D | Common Stock | 5,000 | 17.00 | 85.0K | 557,490 | — | ↗ |
| 2003-11-07 | JAFFE ROSS A MD | Director | J-Other | D | Common Stock | 745,247 | 0.00 | — | 400,000 | — | ↗ |
| 2003-11-03 | LORTZ W MARK | Director / Officer | J-Other | D | Common Stock | 2 | 5.07 | 10.13 | 6,849 | — | ↗ |
| 2003-10-31 | LORTZ W MARK | Director / Officer | S-Sale | D | Common Stock | 15,000 | 18.00 | 270.0K | 562,490 | — | ↗ |
| 2003-08-19 | JAFFE ROSS A MD | Director | J-Other | D | Common Stock | 1,150,000 | 0.00 | — | 1,145,247 | — | ↗ |
| 2003-07-29 | LORTZ W MARK | Director / Officer | S-Sale | D | Common Stock | 45,000 | 15.09 | 679.1K | 532,490 | — | ↗ |
| 2003-07-28 | LORTZ W MARK | Director / Officer | S-Sale | D | Common Stock | 10,000 | 15.00 | 150.0K | 577,490 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-5.6K
Shares Outstanding
6.15B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael I. Ruxin | Chief Medical Officer & Director | 1M | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for THER
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
